Loading...
M. J. Biopharm Private Limited — Ethambutol Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #12 for Ethambutol · $171.1K export value · DGFT Verified
M. J. Biopharm Private Limited is the #12 Indian exporter of Ethambutol with $171.1K in export value and 6 verified shipments. M. J. Biopharm Private Limited holds a 0.0% market share in Ethambutol exports across 1 countries. The company exports 6 pharmaceutical products worth $22.4M across 4 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $5.0M | 100 | 21.6% |
| SOUTH AFRICA | $4.8M | 95 | 20.5% |
| NIGERIA | $2.9M | 57 | 12.3% |
| PHILIPPINES | $2.5M | 51 | 11.0% |
| KENYA | $1.6M | 32 | 6.9% |
| CONGO DR | $1.1M | 21 | 4.5% |
| THAILAND | $1.1M | 21 | 4.5% |
| INDONESIA | $950.0K | 19 | 4.1% |
| PAKISTAN | $850.0K | 17 | 3.7% |
| ETHIOPIA | $850.0K | 17 | 3.7% |
India exports Ethambutol to 133 countries. The top destination is NETHERLANDS (21.6%), followed by SOUTH AFRICA and NIGERIA.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| NATIONAL TUBERCULOSIS AND LEPROSY | NIGERIA | $1.9M | 39 |
| I+SOLUTIONS | NETHERLANDS | $1.2M | 24 |
| SEKRETARIAT DITJEN PENCEGAHAN DAN P | INDONESIA | $900.0K | 18 |
| MINISTRY OF HEALTH OF THE REPUBLIC | ZAMBIA | $650.0K | 13 |
| GDF TILBURG SRS D102TC | NETHERLANDS | $550.0K |
India exported $50.7M worth of Ethambutol through 1,410 shipments from 97 suppliers to 133 countries, serving 458 buyers globally. M. J. Biopharm Private Limited contributes $171.1K to this total, accounting for 0.0% of India's Ethambutol exports.
M. J. Biopharm Private Limited's average Ethambutol shipment value is $28.5K per consignment, based on 6 shipments totaling $171.1K.
M. J. Biopharm Private Limited ranks #12 among 97 Indian Ethambutol exporters with a 0.0% market share. The top 3 exporters are LUPIN LIMITED ($15.8M), MACLEODS PHARMACEUTICALS LTD ($13.3M), MACLEODS PHARMACEUTICALS LIMITED ($6.5M). M. J. Biopharm Private Limited processed 6 shipments to 1 destination countries.
What M. J. Biopharm Private Limited must comply with to export Ethambutol to its top destination countries
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Exporters ranked immediately above and below #12 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 10 | OMNICALS PHARMA PRIVATE LIMITED | $264.3K | 10 | 6 | $26.4K |
| 11 | VERGO PHARMA RESEARCH LABORATORIES PRIVATE LIMITED | $211.2K | 11 | 1 | $19.2K |
| 12 | M. J. BIOPHARM PRIVATE LIMITED ★ | $171.1K | 6 | 1 | $28.5K |
| 13 | PHAR & VIDE | $147.9K | 7 | 2 | $21.1K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 305 | 21.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 246 | 17.4% |
| DELHI AIR CARGO ACC (INDEL4) | 121 | 8.6% |
| DELHI AIR | 113 | 8.0% |
| NHAVA SHEVA SEA (INNSA1) | 94 | 6.7% |
| Bombay Air | 80 | 5.7% |
| JNPT | 67 | 4.8% |
| JNPT/ NHAVA SHEVA SEA | 63 | 4.5% |
M. J. Biopharm Private Limited also exports these tuberculosis medications products. Each links to the detailed product page.
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like M. J. Biopharm. Escalating tensions in the Middle East, particularly the Israel-Iran conflict, have disrupted key shipping routes through the Red Sea and the Suez Canal. Major carriers have suspended or rerouted shipments, leading to increased transit times and freight costs. This situation poses significant logistical hurdles for time-sensitive pharmaceutical exports. (livemint.com)
Conversely, the U.S.-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, potentially benefiting Indian exporters. However, the U.S. has also implemented policies favoring domestic manufacturing, such as the "Buy American" initiative, which could impact Indian companies' access to this lucrative market. (walterhealthcare.co.in)
In the European Union, stringent regulations like the Falsified Medicines Directive necessitate rigorous compliance from exporters. Indian companies must navigate these complex requirements to maintain market access, emphasizing the need for robust quality assurance systems. (ipa-india.org)
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practices (EU GMP) set stringent guidelines to ensure product safety and efficacy. Indian companies have faced challenges, including increased compliance costs and potential reductions in export volumes due to evolving regulations. (transdatanexus.com)
For M. J. Biopharm, maintaining adherence to these standards is crucial to sustain and expand its export markets. Investments in quality control, staff training, and infrastructure are essential to meet the evolving requirements and to build trust with international partners and regulatory bodies.
M. J. Biopharm Private Limited exports 6 products worth $22.4M. Beyond Ethambutol, top products include Insulin, Meropenem, Imipenem, Glibenclamide, Pyrazinamide. View the complete M. J. Biopharm Private Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Ethambutol — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for M. J. Biopharm Private Limited's Ethambutol exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
M. J. Biopharm Private Limited
Full Company Profile →
6 products · $22.4M total trade · 4 categories
| 11 |
| CAMESKIN/CORDAID | CONGO DR | $450.0K | 9 |
| LA PHARMACIE CENTRALE DE TUNISIE | TUNISIA | $150.0K | 3 |
| THE NATIONAL LUNG HOSPITAL | VIETNAM | $100.0K | 2 |
| NATIONAL PROGRAMME FOR TB | SRI LANKA | $100.0K | 2 |
| NATIONAL DRUG SERVICE ORGANISATION | LESOTHO | $100.0K | 2 |
India's Ethambutol is purchased by 458 buyers worldwide. The top buyer is NATIONAL TUBERCULOSIS AND LEPROSY (NIGERIA), followed by I+SOLUTIONS and SEKRETARIAT DITJEN PENCEGAHAN DAN P.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 14 | AVALOR HEALTH CARE PRIVATE LIMITED | $113.6K | 6 | 1 | $18.9K |
M. J. Biopharm Private Limited ranks #12 among 97 Indian Ethambutol exporters. Average shipment value of $28.5K compared to the market average of $522.7K. The closest competitors by value are OMNICALS PHARMA PRIVATE LIMITED and VERGO PHARMA RESEARCH LABORATORIES PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 133+ countries, 458+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for M. J. Biopharm Private Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ethambutol. For current shipment-level data, contact TransData Nexus.